目的：探讨采用非小细胞肺癌患者胸腔积液标本肿瘤细胞进行表皮生长因子(epidermal growth factor receptor，EGFR)基因突变检测的可行性及其临床意义。方法：采用Sanger测序法检测17例非小细胞肺癌患者胸腔积液及对应的17例手术或肺部穿刺组织标本EGFR基因18~21外显子基因突变，并进行统计分析。结果：胸腔积液标本17例共检出5例突变，检出率29.41%。手术或穿刺组织标本17例共检出7例突变，检出率41.18%。胸腔积液标本EGFR基因突变检出率略低于手术或穿刺组织标本。结论：采用Sanger测序法进行非小细胞肺癌患者胸腔积液中EGFR基因突变的检测，方法可行，尤其适用于无法获取手术或肺部穿刺组织标本的患者。
Detection of EGFR mutations and its clinical significance in hydrothorax of patients with non-small cell lung cancer
Objective: To explore the clinical significance of detecting epidermal growth factor receptor (EGFR) mutations in hydrothorax of patients with non-small cell lung cancer (NSCLC). Methods: The mutations of EGFR in exon 18–21 were detected with Sanger sequencing in 17 hydrothorax samples and 17 tumor tissue samples in parallel from patients with NSCLC. Results: There were 5 cases (29.41%) with EGFR mutations in 17 hydrothorax samples and 7 cases (41.18%) in 17 tumor tissue samples. The detection rate of EGFR mutations in hydrothorax samples was lower than that in tumor tissue samples. Conclusion: The hydrothorax sample can be used to detecting EGFR mutations by Sanger sequencing. And it is helpful to patients with NSCLC who can’t obtain tumor tissue.